Blog
RSS FeedPosted by Michael Wonder on 15 May 2026
SMC - May 2026 decisions
11 May 2026 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 15 May 2026
Wegovy and Mounjaro for weight loss not funded
14 May 2026 - PHARMAC has assessed the application to fund Wegovy for weight loss and added it to our ...
Posted by Michael Wonder on 15 May 2026
Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families
14 May 2026 - People living with spinal muscular atrophy in England are set to gain routine access to two potentially ...
Posted by Michael Wonder on 15 May 2026
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
14 May 2026 - Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer. ...
Posted by Michael Wonder on 09 May 2026
Update from the PBAC (April 2026)
7 May 2026 - The PBAC has published its April 2026 update. ...
Posted by Michael Wonder on 08 May 2026
Update to agenda for the July 2026 PBAC meeting (8 May 2026)
8 May 2026 - The agenda for the July 2026 PBAC meeting has now been updated. ...
Posted by Michael Wonder on 08 May 2026
NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed
8 May 2026 - Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following ...
Posted by Michael Wonder on 01 May 2026
Agenda for the May 2026 PBAC meeting
1 May 2026 - The agenda for the May 2026 PBAC meeting is now available. ...
Posted by Michael Wonder on 30 Apr 2026
First NICE recommended treatment for uncontrolled generalised myasthenia gravis
29 April 2026 - We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis whose ...
Posted by Michael Wonder on 30 Apr 2026
Have your say on the framework for consumer engagement in HTA
29 April 2026 - We are developing a framework that sets out guiding principles, focus areas and actions to support ...
Posted by Michael Wonder on 30 Apr 2026
Draft 2026-27 Cost Recovery Implementation Statement for listing medicines on the PBS and designated vaccines on the NIP
30 April 2026 - Consultation on the draft 2026-27 Cost Recovery Implementation Statement (CRIS) for listing medicines on the Pharmaceutical ...
Posted by Michael Wonder on 30 Apr 2026
ICER releases evidence report on treatment for narcolepsy
29 April 2026 - Oveporexton provides a net health benefit compared to currently available treatments; therapy would be cost effective ...
Posted by Michael Wonder on 25 Apr 2026
Highlights from 20-23 April 2026 CHMP meeting
24 April 2026 - The EMA’s CHMP recommended five medicines for approval at its April 2026 meeting. ...
Posted by Michael Wonder on 25 Apr 2026
Novartis receives positive CHMP opinion for Itvisma for spinal muscular atrophy
24 April 2026 - Novartis today announced that the CHMP of the EMA has adopted a positive opinion recommending marketing authorisation ...
Posted by Michael Wonder on 25 Apr 2026
Arrowhead Pharmaceuticals receives positive CHMP opinion recommending approval of Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronaemia syndrome in Europe
24 April 2026 - The CHMP opinion is based on positive results from the Phase 3 PALISADE study where Redemplo ...